<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047095</url>
  </required_header>
  <id_info>
    <org_study_id>123</org_study_id>
    <nct_id>NCT04047095</nct_id>
  </id_info>
  <brief_title>The Efficacy of Early Postoperative Enteral Immunonutrition in Low-Risk Cardiac Surgery Patients</brief_title>
  <official_title>The Efficacy of Early Postoperative Enteral Immunonutrition on Immune Response and Outcomes in Low-Risk Cardiac Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vilnius University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vilnius University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the efficacy of early postoperative enteral&#xD;
      immunonutrition on immune response and outcomes in the low operative risk cardiac surgery&#xD;
      population with low phase angle value measured by the bioelectrical impedance analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study enrolls a low operative risk cardiac surgery patients who undergo elective cardiac&#xD;
      surgery with cardiopulmonary bypass (CPB). Patient is offered to take part in a study a day&#xD;
      prior to surgery. Information is provided regarding protocol, aim and course of study. Only&#xD;
      signing the consent form patients could be enrolled to the study.&#xD;
&#xD;
      Study consists of:&#xD;
&#xD;
      Primary assessment - information about study. Consent form. Assessment of patient according&#xD;
      to predefined criteria. Phase angle evaluation by bioelectrical impedance. (Day prior to&#xD;
      surgery). It is a specific cohort of patients basically governed by surgery risk and the&#xD;
      status of patients' cells. Euroscore II value was used to evaluate the risk of surgery.&#xD;
      Bioelectrical impedance analysis derived phase angle was used to evaluate patients' cells&#xD;
      frailty and vitality.&#xD;
&#xD;
      First phase of blood sampling - blood samples were taken for evaluation immunological status&#xD;
      (cellular and humoral) and inflammatory response (CRB, complete blood count) at the surgery&#xD;
      day morning prior to surgery.&#xD;
&#xD;
      Surgery - evaluating the course of the surgery (see exclusion criteria). Randomization - the&#xD;
      patients will randomly selected into intervention and control groups. The patients,&#xD;
      physicians and investigators were separate from this process. The selection sequence was&#xD;
      computer-generated and provided to the researchers by the statistician.&#xD;
&#xD;
      Intervention - patients in the intervention group received normal daily meals plus one sachet&#xD;
      three times a day of immune nutrients (&quot;Glutamine Plus&quot; by Fresenius Kabi) for five days&#xD;
      after the surgery. The control group was provided with normal daily meals. The patients were&#xD;
      excluded from the study if they failed to intake all of the prescribed immunonutrients.&#xD;
&#xD;
      Second phase of blood sampling - repeated taking of blood samples for evaluation&#xD;
      immunological status (cellular and humoral) and inflammatory response (CRB, complete blood&#xD;
      count) at the sixth day morning after the surgery.&#xD;
&#xD;
      Data collection - data is recorded (demographic data of patients, co-morbidities,&#xD;
      instrumental parameters, phase angle values, surgery course details, immunological assesment&#xD;
      and laboratory tests, short term and long term outcomes).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4+ T cell</measure>
    <time_frame>Six days</time_frame>
    <description>Blood samples were collected twice on the surgery and on the sixth postoperative day by sampling blood for CD4+ T cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD8+ T cell</measure>
    <time_frame>Six days</time_frame>
    <description>Blood samples were collected twice on the surgery and on the sixth postoperative day by sampling blood for CD8+ T cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CD69+ T cell</measure>
    <time_frame>Six days</time_frame>
    <description>Blood samples were collected twice on the surgery and on the sixth postoperative day by sampling blood for CD69+ T cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-1 (IL-1)</measure>
    <time_frame>Six days</time_frame>
    <description>Blood samples were collected twice on the surgery and on the sixth postoperative day by sampling blood for IL-1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-6 (IL-6)</measure>
    <time_frame>Six days</time_frame>
    <description>Blood samples were collected twice on the surgery and on the sixth postoperative day by sampling blood for IL-6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor necrosis factor alfa (TNFα)</measure>
    <time_frame>Six days</time_frame>
    <description>Blood samples were collected twice on the surgery and on the sixth postoperative day by sampling blood for TNFα.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>28 days</time_frame>
    <description>Short-term postoperative outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>28 days</time_frame>
    <description>Short-term postoperative outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU infectious complications</measure>
    <time_frame>28 days</time_frame>
    <description>Short-term postoperative outcome. It was examined deep wound infections, ventilator associated and hospital acquired pneumonia, urinary tract infections, bloodstream infections, catheter-related bloodstream infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Short-term postoperative outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retoracotomy rate</measure>
    <time_frame>28 days</time_frame>
    <description>Short-term postoperative outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Long-term postoperative outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>28 days</time_frame>
    <description>Short-term postoperative outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of rehospitalization</measure>
    <time_frame>2 years</time_frame>
    <description>Long-term postoperative outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal daily meals plus one sachet three times a day of immune nutrients for five days after the surgery.&#xD;
8 a.m. - normal meal plus one sachet immune nutrients&#xD;
1 p.m - normal meal plus one sachet immune nutrients 6 p.m. - normal meal plus one sachet immune nutrients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal daily meals. 8 a.m. - normal meal&#xD;
1 p.m. - normal meal 6 p.m. - normal meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Immunonutrients + normal daily meal</intervention_name>
    <description>&quot;Glutamine Plus&quot; by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g).</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Normal daily meal (75-80 g protein)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Normal daily meal</intervention_name>
    <description>Normal daily meal (75-80 g protein)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  Elective cardiac surgery with cardiopulmonary bypass:&#xD;
&#xD;
          -  coronary artery bypass grafting surgery (CABG);&#xD;
&#xD;
          -  aortic valve replacement;&#xD;
&#xD;
          -  mitral valve replacement;&#xD;
&#xD;
          -  mitral valve repair;&#xD;
&#xD;
          -  tricuspid valve repair;&#xD;
&#xD;
          -  combined operations (CABG and valve surgery);&#xD;
&#xD;
          -  Phase angle &lt;5.5⁰ (phase angle was evaluated one day prior to surgery using&#xD;
             bioelectrical impedance analysis (InbodyS10 device).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Preoperative:&#xD;
&#xD;
          -  previous cardiac surgery;&#xD;
&#xD;
          -  left ventricle ejection fraction &lt;40%;&#xD;
&#xD;
          -  use of preoperative intra-aortic balloon pump (IABP);&#xD;
&#xD;
          -  critical preoperative state;&#xD;
&#xD;
          -  pulmonary artery mean pressure &gt;55 mmHg;&#xD;
&#xD;
          -  diagnosis of infectious endocarditis;&#xD;
&#xD;
          -  pacemaker;&#xD;
&#xD;
        Operative:&#xD;
&#xD;
          -  complicated intraoperative course (unplanned intervention or low cardiac output&#xD;
             syndrome in the operating theatre: failure to wean from cardiopulmonary bypass (CPB)&#xD;
             or intraoperative insertion of IABP or infusion of two or more inotropic medications&#xD;
             with a cumulative dose of 0.2 mcg/kg/min);&#xD;
&#xD;
          -  surgery time &gt;6 h;&#xD;
&#xD;
          -  unplanned intervention;&#xD;
&#xD;
        Postoperative:&#xD;
&#xD;
          -  disturbance of dietary rules.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jurate Sipylaite, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vilnius University, Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marija Svetikiene, MD</last_name>
    <phone>0037061225352</phone>
    <email>marija.svetikiene@santa.lt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donata Ringaitiene, MD, PhD</last_name>
    <email>donata.ringaitiene@santa.lt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marija Svetikiene, MD</last_name>
      <email>marija.svetikiene@santa.lt</email>
    </contact>
    <contact_backup>
      <last_name>Donata Ringaitiene, MD, PhD</last_name>
      <email>donata.ringaitiene@santa.lt</email>
    </contact_backup>
    <investigator>
      <last_name>Donata Ringaitiene, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marija Svetikiene, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jurate Sipylaite, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Viktoras Isajevas, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vilnius University</investigator_affiliation>
    <investigator_full_name>Donata Ringaitiene</investigator_full_name>
    <investigator_title>PhD Vilnius University Institute of Clinical Medicine Clinic of Anaesthesiology and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Cardiac surgery</keyword>
  <keyword>Immunonutrition Glutamine Bioelectrical impedance</keyword>
  <keyword>Immunological status</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

